Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Luspatercept

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Reblozyl

    02 2Reblozyl

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2020 Revenue in Millions : 274

    2019 Revenue in Millions : 0

    Growth (%) : New Launch

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2021 Revenue in Millions : 551

    2020 Revenue in Millions : 274

    Growth (%) : 101

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2022 Revenue in Millions : 717

    2021 Revenue in Millions : 551

    Growth (%) : 30

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Reblozyl

    Luspatercept

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Merck & Co.

    Luspatercept

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 166

    2021 Revenue in Millions : 17

    Growth (%) : 876

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Reblozyl

    Luspatercept-aamt

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Bristol Myers Squibb

    Luspatercept-aamt

    Main Therapeutic Indication : Hematology

    Currency : USD

    2023 Revenue in Millions : 1,008

    2022 Revenue in Millions : 717

    Growth (%) : 41

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Reblozyl

    Luspatercept

    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Brand Name : Reblozyl

    U.S.A
    arrow
    Pharmtech & Ingredients
    Not Confirmed

    Merck & Co.

    Luspatercept

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 212

    2022 Revenue in Millions : 166

    Growth (%) : 28

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF